<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-154855</identifier>
<setSpec>2173-2345</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Osteomalacia in a young adult</dc:title>
<dc:description xml:lang="en">Cases of hypophosphatemic osteomalacia respond to various causes, both genetic and acquired. Some variants of mesenchymal tumors produce inappropriate amounts of fibroblast growth factor 23 (FGF-23), a mediator which induces renal phosphate loss. The biochemical picture is characterized by hypophosphatemia, decreased tubular reabsorption of phosphates, low or inappropriately normal serum calcitriol and high or unusually normal levels of FGF-23 plasma. This paraneoplastic syndrome is called tumorinduced or oncogenic osteomalacia. There are a limited series of published cases, although it has been increasingly accepted in recent years. Diagnosis may be complex given its low incidence, the difficulties in localizing the tumors and heterogeneity in histopathologic interpretation. Complete surgical removal has healed, but there may be recurrences whereas phosphorus and calcitriol oral supplements offer alternative medical treatment (AU)</dc:description>
<dc:creator>Alonso, G</dc:creator>
<dc:creator>Varsavsky, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los cuadros de osteomalacia hipofosfatémica responden a diversas causas genéticas y adquiridas. Algunas variantes de tumores mesenquimales producen cantidades inapropiadas de factor de crecimiento fibroblástico 23 (FGF-23), un mediador que induce una pérdida renal de fosfatos. El cuadro bioquímico se caracteriza por hipofosfatemia, disminución de la reabsorción tubular de fosfatos, niveles bajos o inapropiadamente normales de calcitriol sérico y niveles altos o inapropiadamente normales de FGF-23 plasmático. Este síndrome paraneoplásico es denominado osteomalacia tumoral u oncogénica. Existen limitadas series de casos publicadas, pero su reconocimiento es creciente en los últimos años. El diagnóstico puede ser complejo por su baja incidencia, la dificultosa localización de los tumores y la heterogeneidad en la interpretación histopatológica. La exéresis quirúrgica completa es curativa, pero puede haber recidivas y los suplementos orales de fósforo y calcitriol son alternativas de tratamiento médico (AU)</dc:description>
<dc:source>Rev. osteoporos. metab. miner. (Internet);8(2): 82-86, abr.-jun. 2016. tab, ilus</dc:source>
<dc:identifier>ibc-154855</dc:identifier>
<dc:title xml:lang="es">Osteomalacia en un adulto joven</dc:title>
<dc:subject>^d31565^s22057</dc:subject>
<dc:subject>^d11186^s22073</dc:subject>
<dc:subject>^d31565^s22012</dc:subject>
<dc:subject>^d2151^s22073</dc:subject>
<dc:subject>^d50734^s22000</dc:subject>
<dc:subject>^d31565^s29166</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50734^s22002</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d31395^s22012</dc:subject>
<dc:subject>^d31395^s22057</dc:subject>
<dc:subject>^d10198^s22016</dc:subject>
<dc:subject>^d10198^s22012</dc:subject>
<dc:subject>^d10198^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201606</dc:date>
</metadata>
</record>
</ibecs-document>
